MEDICAL CHEMICAL DEFENSE (EMD)
Abstract
This project provides for the development of medical materiel and other medical equipment items necessary to provide an effective capability for medical defense against chemical warfare agent threats facing U.S. forces in the field. This project supports efforts in the System Development and Demonstration (SDD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic drugs and diagnostic medical devices for the protection, treatment, detection, and medical management of chemical warfare agent exposures. Project funds research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug Administration (FDA) drug licensure application(s). This program currently funds: (1) Bioscavenger (BSCAV), a new capability, to be used as a prophylaxis against nerve agents; and (2) Improved Nerve Agent Treatment System (INATS) an enhanced nerve agent treatment regimen consisting of an improved oxime to replace the current fielded oxime 2-pralidoxime chloride (2-PAM), product formulation enhancements to increase survival, and expanded pretreatment indications for the use of pyridostigmine bromide (PB), the active component of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP).
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2015
- Source ID
- MC5_0604384BP_5_0400_PB_2015
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (EMD)
- Child Accomplishment: 1) BSCAV
- Child Accomplishment: 2) BSCAV
- Child Accomplishment: 3) BSCAV
- Child Accomplishment: 4) BSCAV
- Child Accomplishment: 5) BSCAV
- Child Accomplishment: 6) BSCAV
- Child Accomplishment: 7) INATS
- Child Accomplishment: 8) INATS
- Child Accomplishment: 9) INATS
- Child Accomplishment: 10) INATS